

We claim:

1. A method of treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition which comprises administering to such human in need of such treating and/or preventing an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of montelukast, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the effective amount of loratadine is about 1 mg/day to about 45 mg/day.
3. The method of claim 2, wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.
4. The method of claim 3, wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.
5. The method of claim 4, wherein the effective amount of loratadine is about 10mg/day.
6. The method of claim 1, wherein the allergic and/or inflammatory is seasonal allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.
7. The method of claim 1, wherein the effective amount of montelukast is about 5 mg/day to about 20 mg/day.
8. The method of claim 7, wherein the effective amount of montelukast is about 10 mg/day.
9. A method of treating and/or preventing a cardiovascular disease in a human in need of such treating and/or preventing which comprises administering to such

human in need of such treating and/or preventing an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of montelukast, or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein the effective amount of loratadine is in the

5 range of about 1 mg/day to about 45 mg/day.

11. The method of claim 10, wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.

12. The method of claim 11, wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.

10 13. The method of claim 12, wherein the effective amount of loratadine is about 10 mg/day.

14. The method of claim 9, wherein the effective amount of montelukast is about 5 mg/day to about 20 mg/day.

15. The method of claim 14, wherein the effective amount of montelukast is about

15 10 mg/day.

16. A method of treating and/or preventing a cardiovascular disease in a human suffering from seasonal or perennial allergic rhinitis which comprises administering to such human in need of such treating and/or preventing an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an

20 effective amount of montelukast, or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the effective amount of loratadine is about 1 mg/day to about 45 mg/day.

18. The method of claim 17, wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.

19. The method of claim 18, wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.
20. The method of claim 19, wherein the effective amount of loratadine is about 10 mg/day.
- 5 21. The method of claim 16, wherein the human is suffering from seasonal allergic rhinitis.
22. The method of claim 16, wherein the human is suffering from perennial allergic rhinitis.
- 10 23. The method of claim 16, wherein the effective amount of montelukast is about 5 mg/day to about 20 mg/day.
24. The method of claim 23, wherein the effective amount of montelukast is about 10 mg/day.
- 15 25. A method of treating and/or preventing a cardiovascular disease in a human suffering from atopic dermatitis or urticaria which comprises administering to such human in need of such treating and/or preventing an effective amount of loratadine, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of montelukast, or a pharmaceutically acceptable salt thereof.
26. The method of claim 25, wherein the effective amount of loratadine is about 1 mg/day to about 45 mg/day.
- 20 27. The method of claim 26, wherein the effective amount of loratadine is about 5 mg/day to about 15 mg/day.
28. The method of claim 27, wherein the effective amount of loratadine is about 5 mg/day to about 10 mg/day.

29. The method of claim 28, wherein the effective amount of loratadine is about 10 mg/day.

30. The method of claim 25, wherein the patient is suffering from atopic dermatitis.

5 31. The method of claim 25, wherein the patient is suffering from urticaria.

32. The method of claim 25, wherein the effective amount of montelukast is about 5 mg/day to about 20 mg/day.

33. The method of claim 32, wherein the effective amount of montelukast is about 10 mg/day.